← 返回

靶向肿瘤相关巨噬细胞在胃癌进展和治疗中的作用:从分子机制到治疗应用的见解

英文原题:Targeting tumor-associated macrophages in gastric cancer progression and therapy: insights from molecular mechanisms to therapeutic applications.

查看英文原题

Targeting tumor-associated macrophages in gastric cancer progression and therapy: insights from molecular mechanisms to therapeutic applications.

PubMed 2025/06/17(内容时间) Front Pharmacol Q1 · IF 5.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胃癌(GC)是全球第五大常见恶性肿瘤,给公共卫生带来了沉重负担。胃癌(GC)的系统性治疗,如化疗、靶向治疗和免疫治疗,已取得显著进展。

然而,抗癌药物的广泛应用导致了越来越多与耐药相关的挑战,成为GC治疗中的重大障碍。肿瘤相关巨噬细胞(TAMs)作为GC肿瘤免疫微环境(TIME)中重要的免疫调节因子,因其能够根据环境信号发生可塑性反应,提供了新的治疗靶点。它们与多种免疫细胞和基质细胞类型形成复杂的通讯网络,从而促进了GC中TME的免疫抑制特性。在本综述中,我们构建了GC中巨噬细胞起源和极化的图谱。在癌变过程中,巨噬细胞经历动态的表型转变。

此外,TAMs与肿瘤细胞之间的相互作用显著影响GC的进展,影响肿瘤生长、转移、血管生成和耐药性。此外,这一复杂的免疫调节轴显著增强了对免疫治疗的耐药性,表明靶向TAMs为GC患者提供了重要的治疗机会。TAM清除、TAM再极化和CAR-M疗法等方法已在大量研究中得到验证。

我们还详细阐述了靶向TAMs开发所面临的挑战,这可能为GC治疗提供新的视角。

展开英文摘要原文

Gastric cancer (GC) is the fifth most common malignant tumor that imposes heavily public health burdens worldwide. Systemic therapies for gastric cancer (GC), such as chemotherapy, targeted therapy, and immunotherapy, have undergone significant advancements. Nevertheless, the extensive application of anti-cancer agents has resulted in an increasing array of challenges related to drug resistance, presenting a substantial barrier in GC treatment.

Tumor-associated macrophages (TAMs) as essential immunomodulators within the tumor immune microenvironment (TIME) of GC, providing novel therapeutic targets due to their capacity for plasticity in reaction to environmental signals.

They create a complex network of communication with various immune and stromal cell types, thereby contributing to the immunosuppressive nature of the TME in GC. In this review, we establish the map of the origin and polarization of macrophages in GC. During the process of carcinogenesis, macrophages undergo dynamic phenotypic transitions.

Additionally, the interactions between TAMs and tumor cells significantly influence the progression of GC, affecting tumor growth, metastasis, angiogenesis, and drug resistance.

Furthermore, this intricate immunomodulatory axis notably enhances resistance to immunotherapy, suggesting that targeting TAMs presents substantial therapeutic opportunities for patients with GC. Approaches such as TAM elimination, TAM repolarization, and CAR-M therapy have been validated in numerous studies.

We also elaborate on the challenges faced by the development of targeting TAMs, which may provide innovative perspectives on the GC treatment.

论文信息

作者
Wan C、Deng J、Zhu Y、Wan L、Xu L、Chen Q、Zou C、Huang J
第一作者单位
Department of Gastroenterology, Jian Yang Hospital of Traditional Chinese Medicine, Chengdu, Sichuan, China.China
通讯作者单位
Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.China
文献类型
综述
期刊
Frontiers in pharmacology2025
原文标识
PubMed 40599798 · DOI 10.3389/fphar.2025.1549694